These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35285581)

  • 1. In Situ Tumor Vaccination with Calcium-Linked Degradable Coacervate Nanocomplex Co-Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti-Tumor Immune Responses.
    Liu Y; Li H; Zhao H; Hao Y; Van Herck S; Xu Z; Wang G; Wang X; Zhang X; Ge X; Li X; Yang A; Chen H; Zou J; Wang W; De Geest BG; Zhang Z
    Adv Healthc Mater; 2022 Jun; 11(12):e2102781. PubMed ID: 35285581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
    Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
    Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.
    Xia H; Qin M; Wang Z; Wang Y; Chen B; Wan F; Tang M; Pan X; Yang Y; Liu J; Zhao R; Zhang Q; Wang Y
    Nano Lett; 2022 Apr; 22(7):2978-2987. PubMed ID: 35302770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
    Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
    Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
    Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
    ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Intelligent Nanovehicle Armed with Multifunctional Navigation for Precise Delivery of Toll-Like Receptor 7/8 Agonist and Immunogenic Cell Death Amplifiers to Eliminate Solid Tumors and Trigger Durable Antitumor Immunity.
    Hao Y; Li H; Zhao H; Liu Y; Ge X; Li X; Chen H; Yang A; Zou J; Li X; Sun X; Zhang X; Wang X; Li Z; Zhang Q; Wu H; Wang G; Zhang J; De Geest BG; Zhang Z
    Adv Healthc Mater; 2022 Jun; 11(12):e2102739. PubMed ID: 35306756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
    Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
    PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
    Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
    J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
    Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
    J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.